Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials

Alimujiang, S.; Zhang, Tao; Han, Zhi-Gang; Yuan, Shuai-Fei; Wang, Qiang; Yu, Ting-Ting; Shan, Li

추천

검색

자료유형: 학술저널

저자정보: Alimujiang, S. (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University) Zhang, Tao (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University) Han, Zhi-Gang (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University) Yuan, Shuai-Fei (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University) Wang, Qiang (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University) Yu, Ting-Ting (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University) Shan, Li (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제4호

발행연도: 2013.1

수록면: 2,413 - 2,419 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Use of epidermal growth factor receptor inhibitors (EGFR-TKIs ) is now standard for non-small-cell lung cancer (NSCLC). However, the effects of EGFR-TKIs in maintenance therapy for advanced NSCLC patients are still unclear. The preent meta-analysis was performed to examine pooled data of randomized control trials (RCT) where EGFR-TKIs were compared against placebo in maintenance regimens for patients with advanced NCSLC to quantify potential benefits and determine safety. Methods: Several data bases were searched, including PubMed, EMBASE and CENTRAL, and we performed an internet search of conference literature. The endpoints were objective response rates (ORR), progression-free survival (PFS) and overall survival (OS). We performed a meta-analysis of the published data, using Comprehensive Meta Analysis software (Version 2.0). with a fixed effects model and an additional random effects model, when applicable. The results of the meta-analysis are expressed as hazard ratios (HRs) or risk ratios (RRs), with their corresponding 95% confidence intervals (95%CIs). Results: The final analysis included six trials, covering 3,758 patients. Compared with placebo, EGFR-TKIs maintenance therapy improved ORR and PFS for patients with advanced NSCLC, the difference being statistically significant (P<0.05), but proved unable to prolong patients' OS. The main adverse reactions were diarrhea and rashes. Conclusion: EGFR-TKIs demonstrated encouraging efficacy, safety and survival when delivered as maintenance therapy for patients with advanced NSCLC after first-line chemotherapy, especially for the patients who had adenocarcinomas, were female, non-smokers and patients with EGFR gene mutations.

#EGFR-TKIs #NSCLC #maintenance therapy

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요